How to Buy Mankind Pharma Share?

You can easily buy Mankind Pharma shares in Groww by creating a demat account and getting the KYC documents verified online.

What is the Share Price of Mankind Pharma?

The share price of any stocks is volatile and keeps changing throughout the day owing to different factors. Mankind Pharma share price is ₹0.00 as of 22 May ‘25.

What is the Market Cap of Mankind Pharma?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Mankind Pharma is ₹76,801 Cr as of 22 May ‘25.

What is the PE and PB ratio of Mankind Pharma?

The PE and PB ratios of Mankind Pharma is 49.31 and 9.11 as of 22 May ‘25

What is the 52 Week High and Low of Mankind Pharma?

The 52-week high/low is the highest and lowest price at which a Mankind Pharma stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Mankind Pharma is ₹1,242.00 and ₹2,041.15 as of 22 May ‘25

Mankind Pharma Share Price Today - Mankind Pharma Ltd Stock Price Live NSE/BSE

The current prices are delayed, login to your account for live prices
LOGIN
Create Alert
Watchlist
Mankind Pharma
₹00123456789.0012345678900123456789
0.00 (0.00%) 1D
Manage alerts
Active alerts for Mankind Pharma
ADD NEW ALERT
We are having trouble fetching the graph
Retry
NSE
1D
1W
1M
1Y
3Y
5Y
All
Terminal
Overview
Events
News
Performance
Open
0.00
Prev. Close
0.00
Volume
NA
Total traded value
NA
Upper Circuit
NA
Lower Circuit
NA
Analyst Estimates
45%
Buy
45%
Hold
36%
Sell
18%
Aggregated by Refinitiv from 11  Analysts
I/B/E/S Data Estimates
The Institutional Brokers' Estimate System (I/B/E/S) is a database of estimates made by stock analysts regarding the future earnings of publicly traded companies. It provides analyst forecasts on company performance expressed via various consensus measures, including earnings per share, sales, and net income.
*Disclaimer
These estimates are aggregated by Refinitiv using it’s Institutional Brokers' Estimate System and displayed by us on “AS IS” basis. The estimates that are displayed should not be construed to be investment recommendation/advice or an offer or solicitation of an offer to buy/sell any securities by Nextbillion Technology Pvt Ltd (Groww). Investors should not solely rely on the information displayed herein and must make investment decisions based on their own investment objectives, judgment, risk profile, and financial position. Past performance should not be taken as an indication or guarantee of future performance.  Kindly note that investment in securities markets is subject to market risks, read all the related documents carefully before investing.
FundamentalsMarket Cap₹76,801Cr
ROE18.48%
P/E Ratio(TTM)49.31
EPS(TTM)38.88
P/B Ratio9.11
Dividend Yield0.00%
Industry P/E55.43
Book Value210.40
Debt to Equity0.02
Face Value1
Understand Fundamentals
Financials
Revenue
Profit
Net Worth
*All values are in Rs. Cr
2,4532,1282,1002,6372,768Sep '22Dec '22Mar '23Jun '23Sep '23
Quarterly
Yearly
See Details
About Mankind PharmaMankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It has a portfolio of formulations in several therapeutic areas, such as anti-infectives, cardiovascular, gastrointestinal, vitamins/minerals/nutrients, respiratory, anti-diabetic, dermatology, gynecology, and pain/analgesics, among others. Its other therapeutic areas include urology, ophthalmology, antiparasitic, stomatological, antineoplastic/immunomodulator, hepatoprotective, anti-malarial, blood-related, hormones, antiviral, sex stimulants/rejuvenators, anti-tuberculosis, parenteral and vaccines. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others.;
Parent OrganisationMankind Pharma
Founded1991
Managing DirectorMr. Rajeev Juneja
NSE SymbolMANKIND
Shareholding PatternMar '23
Jun '23
Sep '23
Promoters
76.50%
Retail And Others
14.92%
Foreign Institutions
4.18%
Mutual Funds
3.90%
Other Domestic Institutions
0.50%
See More
Top Mutual Funds Invested(4)FUND NAMEAUM(%)
SBI Healthcare Opportunities Fund Direct Plan Growth4.92%
Motilal Oswal ELSS Tax Saver Fund Direct Growth4.51%
Motilal Oswal Large and Midcap Fund Direct   Growth3.64%
Nippon India Pharma Fund Direct Growth3.08%
Similar StocksCOMPANY52 WEEK
MARKET PRICEP/E Ratio
Sun Pharmaceutical Industries
NA
(0.00%)
34.56
Cipla
NA
(0.00%)
28.21
Dr Reddy's Laboratories
NA
(0.00%)
18.83
Torrent Pharmaceuticals
NA
(0.00%)
54.22
See More

FUND NAME	AUM(%)
SBI Healthcare Opportunities Fund Direct Plan Growth	4.92%
Motilal Oswal ELSS Tax Saver Fund Direct Growth	4.51%
Motilal Oswal Large and Midcap Fund Direct Growth	3.64%
Nippon India Pharma Fund Direct Growth	3.08%

COMPANY	MARKET PRICE	P/E Ratio
Sun Pharmaceutical Industries	NA (0.00%)	34.56
Cipla	NA (0.00%)	28.21
Dr Reddy's Laboratories	NA (0.00%)	18.83
Torrent Pharmaceuticals	NA (0.00%)	54.22

Want to invest in this stock?

Open a free Demat account in minutes to start investing in stocks.

Buy now

Vaishnavi Tech Park, 3rd & 4th Floor
Sarjapur Main Road, Bellandur
Bengaluru – 560103
Contact Us
PRODUCTS
StocksFutures & OptionsIPOMutual FundsCreditBill Payments
GROWW
About UsPricingBlogMedia & PressCareersHelp and Support
QUICK LINKS
AMC Mutual FundsCalculatorsGlossaryOpen Demat AccountGroww DigestSitemap
ⓒ 2016-2025 Groww. All rights reserved, Built with ♥in India

ABOUT GROWW

Groww is India’s growing financial services platform where users can find their investment solutions pertaining to mutual funds, stocks, US Stocks, ETFs, IPO, and F&Os, to invest their money without hassles.

Groww objectively evaluates stocks and mutual funds and does not advise or recommend any stocks, mutual funds or portfolios. Investors shall invest at their own discretion, will and consent. Groww, at any time, does not guarantee fixed returns on the capital invested.

Groww helps investors -

· By providing 100% paperless online free Demat and trading account opening

· By providing an objective evaluation of products available on the platform

· By being transparent about fees and charges involved while investing in a product

· By offering decision-making assistance by providing technical analysis with advanced charts, well-designed line & candlestick charts that indicate share price movements, and market indices, along with more details about all registered and listed companies

SECURE TRANSACTIONS ON GROWW

All transactions on Groww are safe and secure. Users can invest through SIP or Lumpsum using Netbanking through all supported banks. It uses BSE Star MF (with Member code 11724) as transaction platform.

TRADE AND INVEST SECURELY WITH GROWW

Stocks, Mutual fund investments, F&Os, etc., are very popular with individual investors because of their numerous benefits. On Groww, an investor can -

- Invest in Nifty 50 (NSE) & Sensex (BSE) listed stocks

- Diversify across multiple stocks and other instruments

- Start SIP with any amount (as low as Rs. 500)

- Switch regular funds to direct funds

- Start automated monthly investments (SIP), and benefit from many more features

All type of mutual funds are available on Groww.

INVESTING IN MUTUAL FUND PORTFOLIOS

Portfolio is collection of mutual funds designed to meet your investment goals. Investing in mutual fund portfolios helps you in diversifying your investments and reduces the risk. Portfolios also help you in assigning an investment goals and make it easy for you to save for and achieve your goals. You can create a portfolio yourself or ask an expert to build it for you.

ATTENTION INVESTORS

1. For Stock Broking Transaction 'Prevent unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day...Issued in the interest of Investors.

2. For Depository Transaction 'Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL/NSDL on the same day...Issued in the interest of investors.

3. KYC is a one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

4. If you are subscribing to an IPO, there is no need to issue a cheque. Please write the Bank account number and sign the IPO application form to authorize your bank to make payment in case of allotment. In case of non allotment the funds will remain in your bank account.

· Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website.

· Awareness regarding guidelines on Margin collection

1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

3. Pay 20% upfront margin of the transaction value to trade in cash market segment.

4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.

Issued in the interest of Investors

DISCLAIMER

NextBillion Technology Private Limited (CIN: U65100KA2016PTC092879) is a member of NSE & BSE with SEBI Registration no: INZ000301838, Depository Participant of CDSL Depository with SEBI Registration no: IN-DP-417-2019 and Mutual Fund distributor with AMFI Registration No: ARN-111686. Registered office and Correspondence office - No.11, 2nd floor, 80 FT Road, 4th Block, S.T Bed, Koramangala, Bengaluru – 560034. For any grievances related to Stock Broking/DP, please write to grievances@groww.in , please ensure you carefully read the Risk Disclosure Document as prescribed by SEBI.

Procedure to file a complaint on SEBI SCORES: Register on the SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances.

NextBillion Technology Private Limited makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Unless otherwise specified, all returns, expense ratio, NAV, etc are historical and for illustrative purposes only. Future will vary greatly and depends on personal and market circumstances. The information provided by our blog is educational only and is not investment or tax advice.

Mutual fund investments are subject to market risks. Please read all scheme related documents carefully before investing. Past performance of the schemes is neither an indicator nor a guarantee of future performance.

Terms and conditions of the website/app are applicable. Privacy policy of the website is applicable.

Market Cap	₹76,801Cr
ROE	18.48%
P/E Ratio(TTM)	49.31
EPS(TTM)	38.88
P/B Ratio	9.11
Dividend Yield	0.00%
Industry P/E	55.43
Book Value	210.40
Debt to Equity	0.02
Face Value	1

Parent Organisation	Mankind Pharma
Founded	1991

Managing Director	Mr. Rajeev Juneja
NSE Symbol	MANKIND